These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 29134824)

  • 1. An overview of the role of carfilzomib in the treatment of multiple myeloma.
    Ziogas DC; Terpos E; Kastritis E; Dimopoulos MA
    Expert Opin Pharmacother; 2017 Dec; 18(17):1883-1897. PubMed ID: 29134824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A practical review on carfilzomib in multiple myeloma.
    Muchtar E; Gertz MA; Magen H
    Eur J Haematol; 2016 Jun; 96(6):564-77. PubMed ID: 26893241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma.
    Thompson JL
    Ann Pharmacother; 2013 Jan; 47(1):56-62. PubMed ID: 23300152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolution of carfilzomib dose and schedule in patients with multiple myeloma: a historical overview.
    Jakubowiak AJ
    Cancer Treat Rev; 2014 Jul; 40(6):781-90. PubMed ID: 24630735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The mechanism of action, pharmacokinetics, and clinical efficacy of carfilzomib for the treatment of multiple myeloma.
    Pautasso C; Bringhen S; Cerrato C; Magarotto V; Palumbo A
    Expert Opin Drug Metab Toxicol; 2013 Oct; 9(10):1371-9. PubMed ID: 23834482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carfilzomib: a second-generation proteasome inhibitor for the treatment of multiple myeloma.
    McBride A; Klaus JO; Stockerl-Goldstein K
    Am J Health Syst Pharm; 2015 Mar; 72(5):353-60. PubMed ID: 25694410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma.
    Steele JM
    J Oncol Pharm Pract; 2013 Dec; 19(4):348-54. PubMed ID: 23292972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carfilzomib in multiple myeloma.
    Andreu-Vieyra C; Berenson JR
    Expert Opin Biol Ther; 2014 Nov; 14(11):1685-99. PubMed ID: 25170966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma.
    Stewart AK
    Future Oncol; 2015; 11(15):2121-36. PubMed ID: 26125319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comprehensive overview of daratumumab and carfilzomib and the recently approved daratumumab, carfilzomib and dexamethasone regimen in relapsed/refractory multiple myeloma.
    Richard S; Jagannath S; Cho HJ; Parekh S; Madduri D; Richter J; Chari A
    Expert Rev Hematol; 2021 Jan; 14(1):31-45. PubMed ID: 33331794
    [No Abstract]   [Full Text] [Related]  

  • 11. Carfilzomib Triple Combination Therapy: A Review in Relapsed Multiple Myeloma.
    Hoy SM
    Target Oncol; 2016 Apr; 11(2):255-62. PubMed ID: 26972294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carfilzomib: a novel agent for multiple myeloma.
    Redic K
    J Pharm Pharmacol; 2013 Aug; 65(8):1095-106. PubMed ID: 23837578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma.
    Papadopoulos KP; Siegel DS; Vesole DH; Lee P; Rosen ST; Zojwalla N; Holahan JR; Lee S; Wang Z; Badros A
    J Clin Oncol; 2015 Mar; 33(7):732-9. PubMed ID: 25225420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carfilzomib in combination with daratumumab in the management of relapsed multiple myeloma.
    Touzeau C; Antier C; Moreau P
    Future Oncol; 2021 Mar; 17(9):993-998. PubMed ID: 33289427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The European Medicines Agency Review of Carfilzomib for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy.
    Tzogani K; Camarero Jiménez J; Garcia I; Sancho-López A; Martin M; Moreau A; Demolis P; Salmonson T; Bergh J; Laane E; Ludwig H; Gisselbrecht C; Pignatti F
    Oncologist; 2017 Nov; 22(11):1339-1346. PubMed ID: 28935772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteasome inhibitor-based therapy for treatment of newly diagnosed multiple myeloma.
    Vandross A
    Semin Oncol; 2017 Dec; 44(6):381-384. PubMed ID: 29935899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carfilzomib for the treatment of multiple myeloma.
    Lue J; Goel S; Mazumder A
    Drugs Today (Barc); 2013 Mar; 49(3):171-9. PubMed ID: 23527321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of carfilzomib in treatment of newly diagnosed multiple myeloma.
    Strifler S; Knop S
    Future Oncol; 2018 Dec; 14(30):3123-3134. PubMed ID: 30058374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory multiple myeloma harboring t(11,14)(q13;q32): two case reports and a review of the literature.
    Abuelgasim KA; Alherz N; Alhejazi A; Damlaj M
    J Med Case Rep; 2020 Apr; 14(1):54. PubMed ID: 32321588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and rationale of FOCUS (PX-171-011): a randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM).
    Hájek R; Bryce R; Ro S; Klencke B; Ludwig H
    BMC Cancer; 2012 Sep; 12():415. PubMed ID: 22992303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.